Combining chemotherapy with ICIs like nivolumab aims to convert "cold" tumors (non-responsive) into "hot" tumors (immune-active).
The final results of the CheckMate 9X8 trial are expected to validate whether this immunotherapy combination provides a superior progression-free survival (PFS) or overall survival (OS) compared to standard chemotherapy alone. Destro 9x8
While immunotherapy has revolutionized cancer treatment, many colorectal cancers (specifically MSS/pMMR) have historically responded poorly to single-agent immunotherapy. Combining chemotherapy with ICIs like nivolumab aims to